Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02966912 · ClinicalTrials.gov registry record · NA
Magnesium Supplementation for Primary Prevention of Heart Failure in Obesity
A NA study, sponsored by Providence VA Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT02966912 is a NA study that has completed, run by Providence VA Medical Center. The registered enrollment target is 40 participants.
The verdict
NCT02966912, a NA study, has completed, sponsored by Providence VA Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
The objective of this study is to investigate whether nutritional supplementation with magnesium can improve cardiovascular structure and function in participants with obesity - with a long-term goal of preventing clinical heart failure. Specifically, in a randomized open-label pilot study, we will assess whether dietary Magnesium (Mg) supplementation (versus no supplementation) for 24 weeks in obese patients will improve left ventricular (LV) mass.
Interventions
- DIETARY_SUPPLEMENT 400 mg of Magnesium Oxide twice daily for 24 weeks
- OTHER Open label (none)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2016-11 |
| Est. Completion | 2019-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02966912
The ClinicalTrials.gov registry entry for NCT02966912 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Providence VA Medical Center, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 400 mg of Magnesium Oxide twice daily for 24 weeks is the first listed.
NCT02966912 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02966912 about?
NCT02966912 is a clinical study titled "Magnesium Supplementation for Primary Prevention of Heart Failure in Obesity". The objective of this study is to investigate whether nutritional supplementation with magnesium can improve cardiovascular structure and function in participants with obesity - with a long-term goal of preventing clinical heart failure. Specifically, in a randomized open-label pilot study, we will ...
What is the current status of trial NCT02966912?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2016-11. Estimated completion is 2019-09.
What interventions are being tested in trial NCT02966912?
The interventions under investigation include: 400 mg of Magnesium Oxide twice daily for 24 weeks (DIETARY_SUPPLEMENT), Open label (none) (OTHER).
Who is sponsoring clinical trial NCT02966912?
This trial is sponsored by Providence VA Medical Center, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.